Tetra Discovery Partners Featured in Life Science Leader as a Company to Watch

Tetra Discovery Partners

A determined young company revisits a discarded mechanism and finds a new path to broad-based therapeutics for cognition-related diseases such as Alzheimer’s.


Tetra is developing a new class of phosphodiesterase 4 (PDE4)-inhibitor drugs to treat patients with a wide variety of “cognition-impairing” conditions. Its lead product, a PDE4D inhibitor (BPN14770), will enter Phase 1 human trials in Alzheimer’s disease this year, and two other pipeline candidates are PDE4B inhibitors in preclinical development for treating neuroinflammation and traumatic brain injury.

Read the rest of the article.


Leave a Reply

Your email address will not be published. Required fields are marked *